drugset / Trial / NCT02253797

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

NCT02253797

Phase 1 Completed Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to evaluate the pharmacokinetics of Tipranavir and its metabolites including excretion and mass balance of parent compound and radioactivity at steady-state; to isolate, identify and quantify major metabolites of tipranavir in plasma, urine and feces

Timeline

Start
2003-07
Primary completion
2003-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tipranavir Small molecule 500 mg Oral
Background Ritonavir Other / unclassified 200 mg Oral

Indications

No indication recorded.